arrow
T

Tasuku Nakabori

kansai rosai hospital
H指数:17
被引数:1,059

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除肝细胞癌中,比较一线阿替利珠单抗联合贝伐珠单抗后,二线度鲁特韦联合特瑞普利单抗与伦伐替尼的疗效比较

2026-05-070
OA
Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study

胰腺腺鳞癌患者的治疗结局及预后因素:一项单中心回顾性研究

2026-05-011
PRE
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study

老年患者转移性胆道癌化疗疗效的年龄组分析:一项日本癌症登记队列研究

2026-04-080
OAAI
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma

NRF2-COX2-PGE2轴驱动免疫冷肿瘤并预测肝细胞癌对联合免疫治疗的耐药性

2026-01-012
PRE
Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration

衣壳变构调节剂在干扰素给药期间增强乙型肝炎病毒感染的肝细胞的先天免疫应答

2021-08-254
OAAI
Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation

丙型肝炎病毒增强Rubicon表达,导致自噬抑制和细胞内固有免疫激活

2020-09-1719
OAAI
Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway

丙型肝炎病毒感染通过rig-i样解旋酶途径抑制乙型肝炎病毒复制

2020-01-2223
OAAI